Go To Global Site
Welcome to UCB in the United States

Newsroom

Find U.S. news and updates from UCB, a global biopharmaceutical company focused on creating value for people living with severe diseases, such as epilepsy, Parkinson’s disease, psoriasis, osteoporosis, myasthenia gravis,  rheumatoid arthritis, psoriatic arthritis, non-radiographic axial spondyloarthritis, and more. 

Spotlight Story

UCB’s Commitment to Students Living with Epilepsy

Each year, UCB has the honor of awarding our UCB Family Epilepsy Scholarship to deserving individuals living with epilepsy, their family members, and caregivers to help them fulfill their dreams. We realize that to truly make an impact on patients’ lives, we must go beyond developing and delivering medicines, and we are committed to helping patients and their families receive the financial support they need to live their best lives possible.

 

 

UCB U.S. News

Our R&D Response to COVID-19: A Patients’ First Approach

Read More

UCB’s Commitment to Students Living with Epilepsy

Read More

UCB Announces BRIVIACT® (brivaracetam) CV Now FDA-Approved to Treat Partial-Onset Seizures in…

Read More

Twitter Feed

For More Information